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Abstract
Operations research was added as a fourth scientific track to the pathogenesis conference series at the 5
th IAS
Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2009) in recognition of the importance of this
growing research field and the need for applied research to inform and evaluate the scale up of some key inter-
ventions in HIV treatment, care and prevention.
Several studies demonstrated how task shifting and the decentralization of health services can leverage scarce
health care resources to support scale-up efforts. For example, a Ugandan study comparing home-based and facil-
ity-based antiretroviral therapy (ART) delivery found that both delivered equivalent clinical outcomes, but home-
based delivery resulted in substantial cost savings to patients; and a retrospective cohort analysis of an HIV care
programme in Lesotho demonstrated that devolving routine patient management to nurses and trained counsel-
lors resulted in impressive gains in annual enrolment, retention in care and other clinical indicators.
Studies also demonstrated how the use of trained counsellors and public health advisors could effectively expand
both clinical and public health capacity in low-income settings. Studies evaluating the impact of integrating HIV
and TB care resulted in improved treatment outcomes in coinfected populations, the development of environmen-
tal interventions to reduce TB transmission, and uncovering of the extent of multi-drug-resistant and extremely
drug-resistant tuberculosis (MDR-TB and XDR-TB) in KwaZulu-Natal, South Africa.
Some mathematical modelling and cost-effectiveness studies presented at this meeting addressed interventions to
increase retention in care, and strengthened the evidentiary basis for universal voluntary testing and immediate
ART on reducing HIV transmission; debate continued about the relative merits of clinical versus laboratory monitor-
ing. Finally, a provocative plenary presentation outlined the shortfalls of current prevention interventions and
argued for more cost-effectiveness analyses to guide the selection of interventions for maximum benefit.
Discussion
The new operations research track at IAS 2009 reflects
a growing recognition of the need for applied research
to inform the scale up of HIV programmes. The wide
r a n g ea n dq u a l i t yo fp r e s e n t a t i o n sf r o mav a r i e t yo f
disciplines exemplified one of the challenges for the
conference: how to clearly define the operations
research field in order to improve understanding of its
role among investigators and other HIV professionals.
In his summary report, Track D lead rapporteur
George Schmid (World Health Organization, Geneva)
defined operations research as research that “provides
decision makers with information to improve the per-
formance of their programmes ... including identifying
service delivery problems and evaluating a variety of
delivery interventions” [1].
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gramme evaluations; evaluations of various service deliv-
ery models; epidemiology; mathematical modelling; and
cost-effectiveness studies. A pre-conference workshop
convened by the International AIDS Society (IAS) pro-
vided concrete information on how to use operations
research methodologies to strengthen HIV prevention,
care and treatment scale up. The need for new opera-
tions research to further build the evidence base for the
health systems strengthening effects of HIV investments
also dominated discussion at a two-day pre-conference
meeting convened by the IAS.
Strategies for strengthening service delivery
Several studies highlighted how task shifting and the
decentralization of HIV services can leverage scarce
health care resources to support scale-up efforts. Shab-
bar Jaffar (London School of Hygiene and Tropical
Medicine) compared traditional facility-based delivery of
ART with home-based care delivered by trained lay peo-
ple (including medication provision, adherence support
and referrals) in Uganda, and found that both resulted
in excellent and equivalent clinical outcomes based on
mortality, CD4+ count and virologic response. While
the cost of service provision was similar for both mod-
els, the home-based care intervention resulted in sub-
stantially reduced costs for patients [2].
Lipontso Makakole (Scott Hospital, Morija, Lesotho)
presented encouraging results from a retrospective
cohort analysis of a country programme that devolved
routine patient management to nurses and referred
patients coinfected with HIV and TB to specially trained
counsellors. After two years, annual enrolment more
than doubled, the proportion of adults presenting with
less than 50 CD4 cells/mm
3 was reduced from 27% to
13%, and 80% of patients were retained in care [3].
Other presenters offered additional examples of strate-
gies to expand health system capacity. In Rwanda,
Alphonse Kayinanga (Catholic Relief Services/AIDS
Relief) and colleagues documented a programme that
trained community volunteers to screen 3340 HIV-posi-
tive individuals for TB, successfully referring 400 for
clinical assessment [4]. Pius Tih (Baptist Convention
Health Board, Cameroon) described a public health pro-
gramme in Cameroon that used trained health advisors
to conduct contact tracing and partner notification for
individuals testing positive in a high-prevalence region
of the country [5].
Operations research also demonstrated how to better
integrate service delivery among HIV programmes and
among HIV and non-HIV health services. In his plen-
ary presentation, Gerald Friedland (Yale School of
Medicine, New Haven) described how an integrated
HIV and TB treatment programme in KwaZulu-Natal,
South Africa – w h e r em o r et h a n9 0 %o fT Bc a s e sa r e
coinfected with HIV – not only resulted in substan-
tially better clinical outcomes, but also uncovered the
extent of multi-drug- and extremely drug-resistent TB
prevalence and their effect on morbidity and mortality
[6]. Friedland underscored a consistent theme: combi-
nations of activities and approaches (e.g., using a vari-
ety of interventions to reduce clinical and
environmental factors that contribute to the spread of
T B ) ,r a t h e rt h a nas i n g l ea p p r o a c h ,a r el i k e l yt oy i e l d
the most benefit.
The importance of using a combination of
approaches to deliver HIV and related health services
was echoed in other Track D studies on service inte-
gration, including a study of Family Health Interna-
tional programmes in five African countries that
assessed the extent to which reproductive health ser-
vices were integrated into counselling and testing, and
care and treatment programmes. The results suggest
that, beyond condom provision, more work needs to
be done to better integrate HIV with sexual and repro-
ductive health services for women [7].
Not all task-shifting interventions are created equal,
however, as demonstrated by a study presented by Char-
ity Kabondo (University of North Carolina Project,
Lilongwe, Malawi) where trained traditional birth atten-
dants (used by 44% of pregnant women) were used to
expand the delivery of antiretroviral (ARV) prophylaxis
to prevent vertical transmission. Although the use of
traditional birth attendants expanded the use of ARV
prophylaxis beyond traditional facility-based care, fewer
than half of the pregnant women were identified as HIV
positive and less than one-quarter of infants diagnosed
as HIV positive received nevirapine prophylaxis from
traditional birth attendants [8].
Expanding ART access and retention
Yves Souteyrand (WHO, Geneva) presented encouraging
data on increases in ART coverage in 2008, including an
almost 50% one-year increase in coverage among chil-
dren in sub-Saharan Africa [9]. Global ART coverage
is currently estimated at 35% (45% for children under
15 years of age). However, evidence from a number of
operations and clinical research studies demonstrates
that earlier ART initiation for individuals with CD4+
counts under 350 cells/mm
3 results in substantial reduc-
tions in morbidity and mortality. Such evidence is
expected to change World Health Organization norma-
tive guidelines (released in November 2009), thereby
making many more people eligible for treatment and
reducing treatment coverage figures [10].
Against this backdrop, several studies addressed the
vexing problem of ART programme retention. Kenneth
Freedberg (Massachusetts General Hospital, Boston)
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four lost-to-follow-up interventions (elimination of ART
co-payments, provision of free opportunistic infection
medications, increased health care worker training and
coverage of transportation costs), which indicated that
such interventions would be highly cost effective [11].
Based on five years of operations research, Anthony
Harries from the IeDEA Collaboration identified 10
steps to improve access and retention, ranging from
simple monitoring and evaluation activities to creative
reward programmes for overstretched health care
workers [12].
In an excellent overview of male circumcision deliv-
ery in sub-Saharan Africa, Agot Kawango emphasized
that while most countries have completed the neces-
sary situation analyses and taken steps to develop poli-
tical support and community messaging for male
circumcision roll out, health care worker shortages and
health facility preparedness remain significant barriers
to scale up.
Encouragingly, she noted a number of operations
research studies underway aimed at evaluating several
i s s u e sr e l a t e dt or o l lo u t ,i n c l u d i n gs a f e t y ,i m p a c to n
sexual risk behaviours, HIV incidence and the compari-
sons of different intervention models, such as physician
versus non-physician delivery. One study on male cir-
cumcision implementation in Uganda, included in
Kawango’s overview, indicated no significant difference
in adverse event rates by technique, health facility or
cadre of health care worker [13].
In other HIV prevention-related operations research, a
promising modelling study on universal voluntary test-
ing and treatment, presented by Reuben Granich
(WHO, Geneva), demonstrated the potential preventive
effects of this strategy at a population level [14]. Ques-
tions remain on how this population-based approach
could be implemented.
The monitoring debate: the role of laboratory services
While there is consensus regarding the need for a base-
line CD4+ count to guide initial clinical decisions, the
frequency of subsequent CD4+ counts and the use of
viral load monitoring was the subject of substantial
debate at IAS 2009. Peter Mugyenyi (Joint Clinical
Research Centre, Kampala) reported on final results
from the five-year Development of Anti-Retroviral Ther-
apy in Africa (DART) study, which compared clinical to
laboratory monitoring using progression to WHO Stage
4 event or death as endpoints. There was no statistically
significant difference between the two arms within the
first two years and a small, but statistically significant
difference from year three onwards, explained by slightly
later switch rates in the clinical monitoring arm. Never-
theless, survival rate was excellent in both arms, at 87%
and 90% for clinical and laboratory monitoring, respec-
tively (see Figure 1) [15].
A cost-benefit analysis of the DART results indicated
that laboratory monitoring for toxicity was expensive
a n dp r o v i d e dn os i g n i f i c a n tb e n e f i t ,a n dt h a tC D 4 +
monitoring may be cost effective as a targeted (rather
than routine) strategy [16,17]. A modelling study pre-
sented by Sylvia Ojoo (University of Maryland/Institute
for Human Virology, Nairobi) also supported these data,
suggesting that CD4+ count monitoring at six, 36 and
60 months was nearly as clinically effective as monitor-
ing every six months and substantially more cost
effective [18].
Financing and cost effectiveness: more and better
A number of speakers referenced concerns regarding the
potential impact of the global economic recession on
HIV commitments from both government and private
donors. In a provocative plenary presentation, Stefano
Bertozzi (Instituto Nacional de Salud Publica, Mexico
City) argued that while the HIV field has been success-
ful in securing more money for AIDS in recent years, it
has been less successful in getting “less AIDS for the
money”. He pointed out that few cost-effectiveness stu-
dies have been conducted on many common prevention
interventions (see Figure 2), and that too often, inter-
ventions are not chosen strategically or used where they
will have maximum benefit [19]. Bertozzi called for stra-
tegies to improve the efficacy and cost effectiveness of
current interventions, while advocating for additional
investments to close the more than US$8 billion funding
gap.
Paul Sax (Brigham and Women’sH o s p i t a l / H a r v a r d
Medical School, Boston) presented the results of a cost-
effectiveness analysis of ACTG 5164, a trial in which
patients with opportunistic infections were randomized
to receive either early or deferred ART [20]. While the
results are not necessarily generalizable to resource-lim-
ited settings, the finding is consistent with other studies
demonstrating better clinical outcomes and reduced
mortality when ART is initiated for everyone with less
than 350 CD4+ cells/mm3, including the landmark
Comprehensive International Program of Research on
AIDS (CIPRA) HT001 study conducted in Haiti. The
Data Safety and Monitoring Board recently suspended
CIPRA HT001 based on the significant interim differ-
ences between the deferred and early ART initiation
arms [21].
Marielle Bemelmans (Médecins Sans Frontières, Brus-
sels, Thyolo) presented a landmark cost-effectiveness
study of the Médecins Sans Frontières-Ministry of
Health ART programme in Malawi, demonstrating that
a variety of measures, including task shifting, decentrali-
zation of care to health centres and community
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Page 3 of 6Figure 2 Cost-effectiveness data for HIV prevention Sources: Bertozzi S, et al: HIV/AIDS prevention and treatment. In: DCP2; Galarraga et al:
Systematic Review of HIV Prevention Cost Effectiveness, 2008. Working Paper, INSP. New studies (2006-2007), Galarraga et al, 2008
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th IAS Conference on Pathogenesis, Treatment
and Prevention. TUSS103. [15]
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targets (with 78% programme retention by the end of
2007) while keeping the marginal cost of the ART pro-
gramme to €2.6 per inhabitant per year due to econo-
mies of scale [22].
Conclusions
There is some evidence that new operations research
studies presented at IAS 2009 had an immediate impact
on some policy makers in the conference’s host country;
an article published after the conference noted that the
South African National AIDS Council would be meeting
to discuss issuing guidance for earlier ART initiation,
treatment for all infants diagnosed with HIV, and better
integration of TB and HIV programmes [22]. The evi-
dence referenced earlier in this article, which demon-
strates how innovative service delivery models can
successfully leverage community-based resources and lay
workers to deliver HIV and public health interventions
in the face of weak health infrastructure, health care
worker shortages and entrenched HIV stigma, is also
likely to inform the continued roll out of HIV
programmes.
IAS 2009 was a promising debut for the new opera-
tions research track. However, some important pro-
gramme gaps remain. For example, the critical issues of
drug and other medical commodity supply and procure-
ment predictability and forecasting were barely touched
on. In addition, the vast majority of data presented in
this track related to vertical transmission and ART pro-
grammes (including health service integration), with
substantially less attention given to prevention interven-
tions beyond circumcision. This is in part due to the
research focus of submitted abstracts, as well as the IAS
conference’s general focus on biomedical, rather than
behavioural prevention interventions.
However, without rigorous cost effectiveness, model-
ling and programme evaluation studies to help identify
the most effective prevention interventions, the evidence
base for prevention will continue to lag behind that for
care, treatment and support, and questions such as
those posed by Bertozzi will continue to be raised about
whether the HIV field is making the best use of its
hard-won financing.
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